ReferencesCholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-loweringtreatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials ofstatins. Lancet 366:1267-78Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, Camosso-Stefinovic J, Rule C, BrowneN, Ritchie G, Stokes T, Mannan R, Bath P, Brindle P, Gill P, Gujral R, Hogg M, Marshall T, Minhas R,Pavitt L, Reckless J, Rutherford A, Thorogood M, Wood D (2008) Clinical Guidelines and EvidenceReview for Lipid Modification: cardiovascular risk assessment and the primary and secondaryprevention of cardiovascular disease <strong>London</strong>: National Collaborating Centre for Primary Care andRoyal <strong>College</strong> of General Practitioners.Department of Health (2000) National Service Framework for Coronary Heart Disease. The StationaryOffice: <strong>London</strong>Department of Health (2001) National Service Framework for Older People. The Stationary Office:<strong>London</strong>Hennekens CH (1999) Update on aspirin in the treatment and prevention of cardiovascular disease.American Heart Journal 137:S9-S13Joint British Societies (2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovasculardisease in clinical practice. Heart 91S5:v1-52Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing coronary heartdisease. Lancet 353:89-92Marshall T, Rouse A (2002). Resource implications and health benefits of primary prevention strategiesfor cardiovascular disease in people aged 30 to 74: mathematical modelling study. British MedicalJournal 325:197-9Marshall T (2006). Estimating the value of information in strategies for identifying patients at high riskof cardiovascular disease. Informatics in Primary Care 14:85-98NICE (2008) Lipid Modification: Costing Template. NICEScottish Intercollegiate Guidelines Network (2007). Risk estimation and the prevention ofcardiovascular disease. A national clinical guideline. [Online, Accessed November 01 2008] Available athttp://www.sign.ac.uk/pdf/sign97.pdf.Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. (1995). Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland CoronaryPrevention Study Group. New England Joirnal of Medicine 333:1301-7Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-convertingenzymeinhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart OutcomesPrevention Evaluation Study Investigators. New England Journal of Medicine 342:145-53Zeuner, D (2008) Annual Report of the Director of Public Health 2007-2008. Hammersmith and FulhamPCT26
<strong>QOF</strong>+ report on alcoholProposed indicatorsIndicator<strong>QOF</strong>+pointsPaymentstages+ ALCOHOL 1. The percentage of patients on one or morepractice registers for CVD At-Risk, Diabetes, Stroke and TIA,Hypertension and CHD who have had AUDIT-C or FASTrecorded on the practice system within the previous 17months+ ALCOHOL 2. The proportion of patients who screen positiveusing either AUDIT-C or FAST within the previous 17 monthswho are subsequently recorded as having a brief interventionfor alcohol misuse15 20-70%30 40-90%It is prerequisite that in order to receive payment for + ALCOHOL 2, practices have reached thelower threshold for + ALCOHOL 1.Practices may also wish to consider participating in the Directed Enhanced Service (DES) forAlcohol 2009/10 which provides additional incentives for screening newly registered patients inprimary care settings.BackgroundResearch by Kaner et al. (1999a) suggests that up to 98 percent of hazardous and harmfuldrinkers may be missed in primary care due to a reliance on clinical history and signs. Themajority of patients in primary care do not object to being asked about their alcohol consumptionif there are good reasons to do so (Wallace and Haines, 1984; Richmond et al., 1996). Primarycare is an ideal setting within which to deliver brief interventions for alcohol misuse in view of itsaccess to the majority of the population, the absence of stigma attached to attending primarycare settings, the presence of ‘teachable moments’ in consultations about alcohol-relatedillnesses, and the generally high credibility in the community of GPs and other primary careprofessionals (Babor, Ritson and Hodgson, 1986).27